tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000200406 /10-K filed Feb 11, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
HCAMRKLLYABBVJNJPFE
NYSE Health care · Pharmaceuticals

Johnson & Johnson JNJ

JNJ quote by TradingView

Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. 10-K, Item 1

Headquarters
New Brunswick, NJ
CEO
Joaquin Duato
Next results
around Jan 20, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $94.2B through the costs to a net profit of $26.8B · income statement of the 10-K

28% net margin
Revenue to Gross profit: $63.9BRevenue to Cost of revenue: $30.3BGross profit to Net profit: $26.8BGross profit to Costs, tax, other: $37.1B Revenue: $94.2B REVENUE $94.2B +6% Y/Y Gross profit: $63.9B · 68% margin GROSS PROFIT $63.9B 68% margin · +4% Y/Y Cost of revenue: $30.3B · 32% of revenue COST OF REVENUE $30.3B 32% of revenue Net profit: $26.8B · 28% margin NET PROFIT $26.8B 28% margin · +91% Y/Y Costs, tax, other: $37.1B · 39% of revenue COSTS, TAX, OTHER $37.1B 39% of revenue
Gross profit $63.9B 68% margin · +4% Y/Y
Net profit $26.8B 28% margin · +91% Y/Y
The full income statement, year by year

JNJ among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 6.0%, above 41% of 59 peers (their median 7.2%) REVENUE GROWTH 6.0% · above 41% Gross margin: 67.6%, above 60% of 50 peers (their median 64.2%) GROSS MARGIN 67.6% · above 60% Net margin: 16.2%, above 71% of 59 peers (their median 9.5%) NET MARGIN 16.2% · above 71% FCF margin: 20.7%, above 71% of 55 peers (their median 15.2%) FCF MARGIN 20.7% · above 71%
JNJ Peer median Below the median

What changed

6 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 11, 2026 against Feb 13, 2025.

Risk factors
6 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Cash from operations lower than net income
Cash from operations $24.5B vs net income $26.8B (FY ending Dec 28, 2025)
10-K · XBRL
Accounting checks
10 other checks clear, 1 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
1 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Cash from operations lower than net income
    Cash from operations $24.5B vs net income $26.8B (FY ending Dec 28, 2025)
  • Receivables +15.7% vs revenue +6.0% (+9.7 pts)
9 more checks with nothing to note
  • Inventory +14.0% vs revenue +6.0% (+8.0 pts)
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: U.S. Innovative Medicine Rebate Reserves - Managed Care, Medicare and Medicaid; Litigation Contingencies - Talc
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

6 paragraphs in Risk Factors that were not in the 10-K filed Feb 13, 2025. Quoted as filed.

All 6 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    The planned separation of the Company's Orthopaedics business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results In October 2025, the Company announced its intention to separate the Company's Orthopaedics business. The Company is targeting completion of the planned…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$80.0B$85.2B$88.8B$94.2B
Net income$17.9B$35.2B$14.1B$26.8B
Operating cash flow$21.2B$22.8B$24.3B$24.5B
Free cash flow$17.2B$18.2B$19.8B$19.7B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$94.2B ▲ 6.0% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

1 filing in the last 30 days · SEC EDGAR

All filings

About the company

Johnson & Johnson, New Brunswick, NJ · from the 10-K filed Feb 11, 2026

Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.

Headquarters
New Brunswick, NJ
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
January 3
Last results
Oct 13, 2026
Incorporated in
NJ

Email alerts

Sources

The 10-K filed Feb 11, 2026 (open at SEC), compared with the 10-K filed Feb 13, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JNJ/export.csv") into a cell.